{"disease":{"id":"sickle-cell-disease-scd","name":"sickle cell disease scd"},"drugs":{"marketed":[{"drug_id":"oxbryta","indication_name":"Treatment of sickle cell disease (SCD) in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxbryta","generic_name":"Voxelotor","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Hemoglobin S (HbS)","drug_class":"Hemoglobin S polymerization inhibitor","quality_score":10,"revenue":"250","mechanism":"Hemoglobin S polymerization inhibitor that binds HbS 1:1 and increases oxygen affinity."},{"drug_id":"oxbryta","indication_name":"Treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxbryta","generic_name":"Voxelotor","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Hemoglobin S (HbS)","drug_class":"Hemoglobin S polymerization inhibitor","quality_score":10,"revenue":"250","mechanism":"Hemoglobin S polymerization inhibitor that binds HbS 1:1 and increases oxygen affinity."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07532564","title":"Risk Factors, Costs, and Impacts of ED Boarding","phase":"","overall_status":"COMPLETED","enrollment_count":30486,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT04413539","title":"Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of Adults and Parents of Children Living with Sickle- Cell Disease in France","phase":"","overall_status":"COMPLETED","enrollment_count":1088,"lead_sponsor_name":"Argo Sante","has_results":false},{"nct_id":"NCT06941389","title":"Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease","phase":"","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT03814746","title":"Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":255,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06619093","title":"Relationship Between Biological Phenotype, Clinical Severity of Sickle Cell Disease, and Blood Coagulation","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04662931","title":"An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03474965","title":"Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03478917","title":"Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Bimarkers and Chest Imaging","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT04053764","title":"Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03264989","title":"Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06887907","title":"Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT06619197","title":"Exploratory Study on Global Reflexology in Sickle Cell Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06761560","title":"Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":29,"lead_sponsor_name":"Yves Pastore","has_results":false},{"nct_id":"NCT07530965","title":"OMEGA-3-FATTY ACIDS IN CHILDREN WITH SICKLE CELL DISEASE","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT02065596","title":"Hematopoietic Stem Cell Transplant for Sickle Cell Disease","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05565092","title":"Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}